Global Epinephrine Autoinjector Market Growth 2025-2031

Global Epinephrine Autoinjector Market Growth 2025-2031

The global Epinephrine Autoinjector market size is predicted to grow from US$ 2418 million in 2025 to US$ 3682 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031.

Epinephrine is the only treatment for a severe allergic reaction known as anaphylaxis (anna-fih-LACK-sis). Epinephrine comes in the form of easy-to-use auto-injectors. It is only available through a prescription by doctors. Each prescription comes with two auto-injectors in a set.



Epinephrine auto-injector is an emergency injection ("shot") of epinephrine. It is used against life-threatening allergic reactions such as severe swelling, breathing problems, or loss of blood pressure.

Global Epinephrine Autoinjector key players include Mylan, Amneal pharma, Kaleo, etc. Global top three players hold a share about 25%.

North America is the largest market, with a share about 70%, followed by Europe and Asia-Pacific, having a total share about 25 percent.

In terms of product, 0.15 mg is the largest segment, with a share about 65%. And in terms of application, the largest application is people who are Under 6 Years, followed by people who are 6 to 12 Years and Over 12 Years.

LP Information, Inc. (LPI) ' newest research report, the “Epinephrine Autoinjector Industry Forecast” looks at past sales and reviews total world Epinephrine Autoinjector sales in 2024, providing a comprehensive analysis by region and market sector of projected Epinephrine Autoinjector sales for 2025 through 2031. With Epinephrine Autoinjector sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Epinephrine Autoinjector industry.

This Insight Report provides a comprehensive analysis of the global Epinephrine Autoinjector landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Epinephrine Autoinjector portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Epinephrine Autoinjector market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Epinephrine Autoinjector and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Epinephrine Autoinjector.

This report presents a comprehensive overview, market shares, and growth opportunities of Epinephrine Autoinjector market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
0.30 mg
0.15 mg

Segmentation by Application:
Under 6 Years
6 to 12 Years
Over 12 Years

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Mylan
Sanofi
ALK Abello
Impax

Key Questions Addressed in this Report

What is the 10-year outlook for the global Epinephrine Autoinjector market?

What factors are driving Epinephrine Autoinjector market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Epinephrine Autoinjector market opportunities vary by end market size?

How does Epinephrine Autoinjector break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.